ABEO
Abeona Therapeutics Inc.
There isn't enough reported data to score ABEO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ABEO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
ABEO's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABEO PE Valuation
ABEO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABEO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABEO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ABEO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.09 | -192% |
| Q2 2026 | -$1.11 | -271% |
| Q1 2026 | $0.95 | +$2.27 |
| Q4 2025 | $1.01 | +$3.25 |
| Q3 2025 | $1.18 | +$3.82 |
| Q2 2025 | $0.65 | +$3.14 |
| Q1 2025 | -$1.32 | +$1.83 |
| Q4 2024 | -$2.24 | +$0.29 |
ABEO has swung to a loss: it lost $1.09 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ABEO on earnings quality, reporting a profit while its opponent remains loss making.
ABEO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.4M | +2745% |
| Q2 2023 | $3.5M | +250% |
ABEO's revenue has grown year over year for four quarters in a row: $13M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | N/A |
| Q2 2026 | -120% | +5578 points |
| Q1 2026 | -264% | N/A |
| Q4 2025 | -423% | N/A |
| Q2 2025 | -5698% | N/A |
| Q2 2023 | -302% | +499 points |
| Q4 2022 | -19024% | N/A |
| Q2 2022 | -801% | N/A |
ABEO's operating margin was −96% last quarter, up 5602 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ABEO on profitability, with a higher operating margin.
ABEO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.5M | +$15.2M |
| Q2 2026 | -$18M | +$3.7M |
| Q1 2026 | -$20.7M | -$936K |
| Q4 2025 | -$19.1M | -$1.9M |
| Q3 2025 | -$23.7M | -$11.1M |
| Q2 2025 | -$21.7M | -$8.3M |
| Q1 2025 | -$19.8M | -$4.5M |
| Q4 2024 | -$17.2M | -$7.9M |
ABEO has burned cash in almost every quarter: −$66M over the past year, against −$82M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ABEO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABEO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +810K shares |
| 1 year | +6.7% | +3.6M shares |
| 3 years | +221% | +39.8M shares |
| 5 years | +1461% | +54.2M shares |
| Available history | +2543% | +55.7M shares |
ABEO has 58M diluted shares, up 6.7% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ABEO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABEO Net Leverage
ABEO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ABEO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.4 | Oversold |
| Stochastic | 3.4 | Oversold |
ABEO's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABEO PE vs Healthcare Sector
| Metric | ABEO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABEO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABEO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.38 | 48% below |
| 20 week MA | $5.50 | 58% below |
| 50 week MA | $5.34 | 57% below |
| 100 week MA | $5.51 | 58% below |
| 200 week MA | $5.09 | 55% below |
ABEO is in a downtrend: it's below all five of its weekly moving averages, and 55% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABEO on trend strength, trading above more of its moving averages.
ABEO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.5 | $43.3 | -49% |
| 2021 | $43.3 | $9.00 | -79% |
| 2022 | $9.00 | $2.51 | -72% |
| 2023 | $2.51 | $5.01 | +100% |
| 2024 | $5.01 | $5.63 | +12% |
| 2025 | $5.63 | $5.45 | -3.2% |
| 2026 YTD | $5.45 | $2.29 | -58% |
ABEO has finished lower in four of the last six years. It's down 58% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ABEO on returns for 2026, with the stronger performance.